REAL WORLD EVIDENCE ON THE BURDEN OF ILLNESS EXPERIENCED BY PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND SYSTEMIC MYCOSES

EHA Library, Anna Forsythe, 214741

EVALUATION OF FOOD EFFECT ON PHARMACOKINETICS OF IVOSIDENIB (AG-120), AN ORAL, POTENT, TARGETED, SMALL MOLECULE INHIBITOR OF MUTANT IDH1, IN HEALTHY SUBJECTS

EHA Library, Bin Fan, 214742

AZACITIDINE FRONTLINE AND SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA PATIENTS. CLINICAL EXPERIENCE AND DEVELOPMENT OF RISK SCORE

EHA Library, Silvia Imbergamo, 214743

MYELOID SARCOMAS IN AML TRANSLOCATION (8;21) IS IT STILL A FAVOURABLE RISK GROUP?

EHA Library, Rohan Halder, 214744

AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA: DURABILITY OF RESPONSE IN ZUMA-1

EHA Library, Olalekan O. Oluwole, 214745

THE NOVEL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES GOOD TOLERABILITY AND CLINICAL RESPONSE IN A PHASE 2A STUDY IN RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA

EHA Library, Steven Horwitz, 214746

THE COMBINATION OF IBRUTINIB, LENALIDOMIDE, AND RITUXIMAB (IR2) IS ACTIVE IN RELAPSED/REFRACTORY (R/R) NON−GERMINAL CENTER-LIKE (NON-GCB) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): INTERIM ANALYSIS

EHA Library, Radhakrishnan Ramchandren, 214747

QUALITY OF LIFE IN CUTANEOUS T-CELL LYMPHOMA SUBJECTS TREATED WITH THE ANTI-CCR4 MONOCLONAL ANTIBODY MOGAMULIZUMAB VERSUS VORINOSTAT: RESULTS FROM THE PHASE 3 MAVORIC TRIAL

EHA Library, Pietro Quaglino, 214748

ANALYSIS OF CNS RELAPSES RISK FACTORS IN A POPULATION OF 1615 UPFRONT DLBCL PATIENTS TREATED IN LYSA PROTOCOLS LNH03 AND LNH07-3B

EHA Library, Sophie Bernard, 214749

SUBSTITUTION OF CISPLATIN FOR CARBOPLATIN OR OXALIPLATIN IN THE DHAP REGIMEN IS ASSOCIATED WITH IMPROVED SURVIVAL IN RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMAS

EHA Library, Eloit Martin, 214750

VCAP-AMP-VECP VERSUS CHOP AS FIRST-LINE CHEMOTHERAPY FOR AGGRESSIVE ADULT T-CELL LEUKEMIA-LYMPHOMA: A PROPENSITY SCORE ANALYSIS

EHA Library, Shigeo Fuji, 214751

POSSIBLE FACTORS ON EFFICACY AND SAFETY OF CAR–T THERAPY IN RELAPSED OR REFRACTORY AGGRESSIVE B-CELL LYMPHOMA

EHA Library, Haiwen Huang, 214752

TITLE: LENALIDOMIDE PLUS R-CHOP THERAPY PROVIDES DURABLE LONG-TERM REMISSIONS IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): COMBINED ANALYSIS FROM TWO PHASE 2 TRIALS.

EHA Library, Annalisa Chiappella, 214753

FRONT-LINE TREATMENT OF DLBCL WITH 6 VERSUS 8 CYCLES OF R-CHOP IS NOT ASSOCIATED WITH INFERIOR SURVIVAL IN ELDERLY PATIENTS: RESULTS FROM A RETROSPECTIVE ANALYSIS OF THE SEER-MEDICARE DATABASE

EHA Library, Aijing Shang, 214754

MONITORING OF RHOA G17V MUTATION DURING THE COURSE OF THERAPY IN PATIENTS WITH ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA BY QUANTITATIVE ALLELE-SPECIFIC PCR WITH LNA-MODIFIED PRIMERS

EHA Library, Yulia Sidorova, 214755

CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOME OF ELDERLY SYSTEMIC T/NK CELL LYMPHOMA IN A RESOURCE-LIMITED COUNTRY: THE RESULT OF THAILAND NATIONWIDE LYMPHOMA REGISTRY

EHA Library, Kitsada Wudhikarn, 214756

RETROSPECTIVE ANALYSIS OF PATIENTS WITH PRIMARY CENTRAL NERVOUS LYMPHOMAS TREATED WITH METHOTREXATE-BASED REGIMEN FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT AND TEMOZOLOMIDE MAINTENANCE

EHA Library, Maria Ljungqvist, 214757

RITUXIMAB, GEMCITABINE AND OXALIPLATIN (R-GEMOX) IN REFRACTORY/RELAPSED PATIENTS NOT CANDIDATES FOR HIGH-DOSE THERAPY WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). A SINGLE CENTER STUDY OF 115 PATIENTS

EHA Library, Clarisse Cazelles, 214758

THE HIGH EXPRESSION OF CD38 IS ASSOCIATED WITH POOR PROGNOSIS IN DE NOVO DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Kaoru Sueoka, 214759

PROGNOSTIC FACTORS IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) UNDER RITUXIMAB-CHOP (R-CHOP) CHEMOTHERAPY WITH OR WITHOUT RADIOTHERAPY (RT)

EHA Library, Theodoros Vassilakopoulos, 214761

SOLUBLE INTERLEUKIN-2 RECEPTOR AS A SURROGATE BIOMARKER OF METABOLIC TUMOR VOLUME MEASURED BY 18F-FDG PET/CT IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Hajime Senjo, 214762

TAK-659 PLUS BENDAMUSTINE (+/-RITUXIMAB), GEMCITABINE, LENALIDOMIDE, OR IBRUTINIB IN PATIENTS (PTS) WITH ADVANCED NON-HODGKIN LYMPHOMA (NHL)

EHA Library, Sarit Assouline, 214763

82RB PET FOR EARLY DETECTION OF DOXORUBICIN-INDUCED CARDIOTOXICITY

EHA Library, Adam Høgsbro Laursen, 214764

IMPACT OF OMISSION/REDUCTION OF VINCRISTINE FROM R-CHOP THERAPY IN TREATMENT OF GCB TYPE DLBCL

EHA Library, Shoko Marshall, 214765

EPIDEMIOLOGY AND TREATMENT PATTERNS IN LATIN AMERICAN PATIENTS WITH NON-HODGKIN’S LYMPHOMA: FINDINGS FROM THE HEMATO-ONCOLOGY IN LATIN AMERICA (HOLA) OBSERVATIONAL REGISTRY STUDY

EHA Library, Miguel Pavlovsky, 214766

CLINICAL RESPONSE AND PHARMACOKINETICS OF BENDAMUSTINE AS A COMPONENT OF SALVAGE R-B(O)AD THERAPY FOR THE TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)

EHA Library, Deok-Hwan Yang, 214767

OUTPATIENT SYSTEMIC HIGH-DOSE METHOTREXATE AS CNS PROPHYLAXIS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Ruben Fernandez, 214768

OUTCOME OF A 10-YEAR POPULATION-BASED COHORT OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN THE FIRST-LINE, REFRACTORY AND RELAPSED SETTING: ‘REAL-WORLD’ DATA IDENTIFY SUBGROUPS IN NEED OF NEW THERAPIES

EHA Library, Hilde van der Galien, 214769

LOW SUNLIGHT EXPOSURE AT TIME OF DLBCL DIAGNOSIS MAY BE ASSOCIATED WITH INFERIOR SURVIVAL IN ELDERLY WOMEN

EHA Library, Anna Elinder Camburn, 214770

THE PROGNOSTIC ROLE OF 18FDG-PET/TAC AT THE END OF FIRST LINE CHEMO-IMMUNOTHERAPY IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: A MONOCENTRIC STUDY ON 308 PATIENTS.

EHA Library, Elena Maiolo, 214771

CLINICAL CHARACTERISTICS AND OUTCOMES OF BURKITT LYMPHOMA IN A DEVELOPING COUNTRY

EHA Library, Vanderson Rocha, 214772

AN INCREASED RISK OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN CHILDREN AFTER CARDIAC TRANSPLANTATION FOR CONGENITAL HEART DISEASE

EHA Library, Ugonna Offor, 214773

ASSESSMENT OF IMMUNE FUNCTION BEFORE AND AFTER TREATMENT WITH RECOMBINANT FACTOR VIII FUSED WITH FC FRAGMENTS

EHA Library, Stephanie Png, 214774

FACTOR VIII RECOVERY TEST IN PERIOPERATIVE MANAGEMENT OF ORTHOPEDIC SURGERY IN ADULT PATIENTS WITH SEVERE HEMOPHILIA A

EHA Library, Jae Joon Han, 214775

PREDICTION OF INHIBITORS IN HAEMOPHILIA PATIENTS BY SCORE IN ONE CENTER

EHA Library, Oleksandra Stasyshyn, 214776

REAL WORLD SWITCHING FROM CONVENTIONAL FVIII PRODUCTS TO RFVIIIFC IN FRANCE, GERMANY, ITALY AND THE UK

EHA Library, Persefoni Kritikou, 214777

MYPKFIT HEMOPHILIA EXPERIENCE IN PEDIATRIC CASES

EHA Library, Selin Aytac, 214778

CHALLENGES OF MANAGEMENT OF REFUGEE CHILDREN WITH CONGENITAL FACTOR DEFICIENCIES

EHA Library, Gul Ozdemir, 214779

PROTEIN EXPLORER IN THE CONTEXT OF OVERLAP OF BONE MARROW FAILURE DISORDERS

EHA Library, Ayodele Alaiya, 214780

NOVEL MUTATIONS IN PATIENTS WITH TELOMEROPATHIES

EHA Library, Monika Haubitz, 214781

RA101495, A SUBCUTANEOUSLY-ADMINISTERED PEPTIDE INHIBITOR OF COMPLEMENT COMPONENT C5, FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: PHASE 2 RESULTS

EHA Library, Anita Hill, 214782

DIFFICULTIES IN DIAGNOSIS AND MANAGEMENT IN PATIENTS WITH CYCLIC NEUTROPENIA

EHA Library, Cornelia Zeidler, 214783

CLINICAL AND MORPHOLOGIC PREDICTORS OF OUTCOME IN APLASTIC ANEMIA PATIENTS TREATED WITH ELTROMBOPAG

EHA Library, Bruno Fattizzo, 214784

A COMPARATIVE STUDY OF INTENSIVE IMMUNOSUPPRESSIVE THERAPY AND HAPLOIDENTICAL TRANSPLANTATION FOR YOUNG SEVERE APLASTIC ANEMIA

EHA Library, Miao Chen, 214785

EFFECTIVENESS OF ECULIZUMAB IN PNH PATIENTS RECEIVING CONCOMITANT IMMUNOSUPPRESSIVE THERAPY

EHA Library, Anita Hill, 214786

EFFECT OF ECULIZUMAB ON TRANSFUSION NEEDS IN PNH PATIENTS WITH AND WITHOUT TRANSFUSION HISTORY

EHA Library, Alexander Röth, 214787

PROGNOSTIC SIGNIFICANCE OF RENAL DYSFUNCTION DURING THE CLINICAL COURSE IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A KOREAN MULTICENTER STUDY

EHA Library, Yeung-Chul Mun, 214788

COMPLEMENT ACTIVATION AND EXACERBATION OF HAEMOLYSIS SECONDARY TO RESPIRATORY VIRAL INFECTIONS IN PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (PNH) PATIENTS TREATED WITH ECULIZUMAB

EHA Library, Ioanna Lazana, 214789

RESULTS OF COBALT, A PHASE II CLINICAL TRIAL OF COVERSIN IN PNH

EHA Library, Anita Hill, 214790

THE INCIDENCE OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CELL CLONES IN THE NORDIC COUNTRIES

EHA Library, Christian Kjellander, 214791

INTERROGATION OF HAEMATOPOIETIC BONE MARRROW PROGENITORS FOR DRIVER MUTATIONS OF CHRONIC LYMPHOCYTIC LEUKAEMIA

EHA Library, David Bruce, 214792

SMG1 LOSS ENHANCES MTOR SIGNALLING IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

EHA Library, Tara Roberts, 214793

TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER CHEMOIMMUNOTHERAPY AND IBRUTINIB

EHA Library, Luca Vincenzo Cappelli, 214794

PAPTP LEADS TO NEOPLASTIC CELL APOPTOSIS IN THE EΜ-TCL1 CHRONIC LYMPHOCYTIC LEUKEMIA MOUSE MODEL

EHA Library, Filippo Severin, 214795

OVERTIME ASSESSMENT OF EPIGENETIC PROFILES IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH CHEMOIMMUNOTHERAPY

EHA Library, Maria Tsagiopoulou, 214796

JAK/SYK INHIBITION IS VITAL TO PREVENT B CELL RECEPTOR SIGNALING AND ITS REGULATION BY THE TUMOUR MICROENVIRONMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Andrew J. Steele, 214797

CLL-DERIVED EXOSOMES REPROGRAM THE PHOSPHOPRTEOMICS LANDSCAPE OF ENDOTHELIAL CELLS.

EHA Library, Lian Lipshtein, 214798

CHRONIC LYMPHOCYTE LEUKEMIA CELLS SHARE A UNIQUE CIRCULAR RNA EXPRESSION PATTERN

EHA Library, Oshrat Raz, 214799

T CELL CLONAL DYNAMICS ARE ASSOCIATED WITH CLINICAL RESPONSE AFTER LENALIDOMIDE CONSOLIDATION TREATMENT IN CLL

EHA Library, Anastasia Hadzidimitriou, 214800

PREVALENCE AND PROGNOSTIC IMPACT OF THE IGLV3-21 G110R MUTATION IN CLL – A PATHOBIOLOGICAL REDEFINITION OF THE UNFAVORABLE CLL SUBTYPE II

EHA Library, Hendrik Veelken, 214801

EVOLUTION OF GENOMIC ABNORMALITIES DURING CLL DISEASE COURSE IS ASSOCIATED WITH TELOMERE LENGTH CHANGES

EHA Library, Helena Olbertova, 214802

NOTCH1, TP53, SF3B1, ATM AND BIRC3 GENE MUTATIONS ARE ASSOCIATED WITH A WORSE OUTCOME IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 13Q LOSSES

EHA Library, Ana E Rodríguez-Vicente, 214803

CHARACTERIZATION OF A NOVEL ENTITY IN CLL: SYMPTOMATIC BRONCHIAL INVOLVEMENT; A STUDY OF THE FRENCH INNOVATIVE LEUKEMIA ORGANIZATION (FILO) GROUP

EHA Library, Morgane Nudel, 214804

GENETIC ABERRATIONS AND PROGRESSION-FREE SURVIVAL IN CLL PATIENTS TREATED WITH FRONT LINE RITUXIMAB-BASED CHEMOIMMUNOTHERAPY (FCR/BR): CLINICAL PRACTICE EXPERIENCE

EHA Library, Michaela Spunarova, 214805

CIRCULATING SEX HORMONES AND NUCLEAR HORMONE RECEPTOR EXPRESSION ARE ASSOCIATED WITH TREATMENT-FREE SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Katrina Vanura, 214806

DESIGN AND MINION TESTING OF A NANOPORE SEQUENCING SPECIFIC GENE PANEL FOR CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Francesco ALBANO, 214807

LOW CATALASE EXPRESSION CONFERS REDOX HYPERSENSITIVITY AND IDENTIFIES AN INDOLENT CLINICAL BEHAVIOR IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Maria SCUPOLI, 214808

STAT3 AND STAT5B MUTATIONS IN LARGE GRANULAR LYMPHOCYTES LYMPHOCYTOSIS/LEUKEMIAS: DIAGNOSTIC AND PROGNOSTIC VALUE

EHA Library, Alberto Orfao, 214809

T-PLL CELLS RESEMBLE MEMORY-TYPE T-CELLS WITH ABERRANT EFFECTOR FUNCTIONS IMPLICATING A LEUKEMOGENIC COOPERATION OF TCL1A WITH TCR SIGNALING

EHA Library, Sebastian Oberbeck, 214810

INTEGRATED GENETIC PROFILES OF T-PLL IMPLICATE A TCL1/ATM-CENTERED MODEL OF ABERRANT DNA DAMAGE RESPONSES

EHA Library, Alexandra Schrader, 214811

CG’806, A NON-COVALENT PAN-FLT3/PAN-BTK INHIBITOR, EXHIBITS UNIQUE BINDING TO WILD TYPE AND C481S MUTANT BTK AND GREATER POTENCY THAN IBRUTINIB AGAINST MALIGNANT B CELLS

EHA Library, Hongying Zhang, 214812

DISTINCT IMMUNE SIGNATURES IN CHRONIC LYMPHOCYTIC LEUKEMIA AND RICHTER’S SYNDROME

EHA Library, Yucai Wang, 214813

DURABILITY OF RESPONSE TO VENETOCLAX (VEN) IN PATIENTS WITH CLL RELAPSED/REFRACTORY TO IBRUTINIB AND/OR IDELALISIB

EHA Library, John C. Byrd, 214814

SALVAGE USE OF IBRUTINIB AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA OR MANTLE CELL LYMPHOMA : A STUDY ON BEHALF OF THE SFGM-TC AND THE EBMT

EHA Library, Mauricette Michallet, 214815

MANAGEMENT, ADVERSE EVENTS, AND OUTCOMES OF 282 CLL PATIENTS (PTS) TREATED WITH VENETOCLAX (VEN) IN THE REAL WORLD

EHA Library, Chadi Nabhan, 214816

IBRUTINIB FOR FIRST-LINE TREATMENT OF OLDER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): A 4-YEAR EXPERIENCE FROM THE RESONATE-2 STUDY

EHA Library, Jan Burger, 214817

IMPACT OF TP53-MUTATED CLONE SIZE ON OUTCOME OF RELAPSED/REFRACTORY (R/R) CLL PATIENTS TREATED WITH VENETOCLAX PLUS RITUXIMAB WITHIN THE PHASE 3 MURANO STUDY

EHA Library, Arnon Kater, 214818

SAFETY ANALYSIS OF VENETOCLAX AND IBRUTINIB FOR PREVIOUSLY TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FIRST INTERIM ANALYSIS FROM THE PHASE II VISION HO141 TRIAL

EHA Library, Carsten Niemann, 214819

EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: UPDATED RESULTS FROM THE NCRI RIALTO TRIAL.

EHA Library, Andrew Pettitt, 214820

OBINUTUZUMAB PRE-INDUCTION ABROGATES HIGH TUMOR LYSIS RISK OF VENETOCLAX IN TREATMENT NAÏVE FCR-UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A PLANNED INTERIM ANALYSIS.

EHA Library, Mark David Levin, 214821

CONTINUING REMISSIONS AFTER VENETOCLAX AND OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND COEXISTING MEDICAL CONDITIONS

EHA Library, Kirsten Fischer, 214822

TWO-COHORT, PHASE II STUDY IN R/R CLL (COSMOS): FIRST PRELIMINARY SAFETY AND EFFICACY RESULTS OF MOR208 TREATMENT IN COMBINATION WITH IDELALISIB IN PATIENTS WHO DISCONTINUED PRIOR IBRUTINIB THERAPY

EHA Library, Wojciech Jurczak, 214823

REAL-WORLD RESULTS ON IBRUTINIB IN RELAPSED / REFRACTORY CLL: 30-MONTH FOLLOW-UP OF 95 SWEDISH PATIENTS TREATED IN A COMPASSIONATE USE PROGRAM

EHA Library, Maria Winqvist, 214824

ANALYSIS OF SUSTAINED HEMATOLOGIC IMPROVEMENT WITH IBRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA

EHA Library, William Wierda, 214825

REAL WORLD TREATMENT PERSISTENCE OF AUSTRALIAN IBRUTINIB PATIENTS IN A NAMED PATIENT PROGRAM

EHA Library, Constantine Tam, 214826

THE EFFICACY OF DUVELISIB MONOTHERAPY FOLLOWING DISEASE PROGRESSION ON OFATUMUMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL OR SLL IN A PHASE 3 CROSSOVER EXTENSION STUDY

EHA Library, Peter Hillman, 214827

A PHASE 1 DOSE ESCALATION STUDY OF ARQ 531 IN SELECTED PATIENS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

EHA Library, Jennifer Woyach, 214828

EFFECTIVENESS OF IBRUTINIB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA IN DAILY PRACTICE IN THE NETHERLANDS: A NATIONWIDE POPULATION-BASED COHORT STUDY

EHA Library, Lina van der Straten, 214829

RAPID DOSE ESCALATION OF VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA PREVIOUSLY TREATED WITH B-CELL RECEPTOR INHIBITOR THERAPY

EHA Library, Kristin Koenig, 214830

INDIRECT TREATMENT COMPARISON OF VENETOCLAX PLUS RITUXIMAB WITH B-CELL RECEPTOR INHIBITORS IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Anthony Mato, 214831

INHIBITION OF NUCLEOCYTOPLASMIC EXPORT ENHANCES SELECTIVE ELIMINATION OF LEUKEMIC STEM CELLS IN CHRONIC MYELOID LEUKEMIA

EHA Library, Michael W Deininger, 214832

IMMUNOMODULATORY EFFECTS OF IFN-ΑLPHA ON T AND NK CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN DEEP MOLECULAR RESPONSE IDENTIFY POTENTIAL CANDIDATES FOR TREATMENT DISCONTINUATION

EHA Library, Massimo Breccia, 214833

IDENTIFICATION OF GENES DIFFERENTLY EXPRESSED BETWEEN BONE MARROW CD34+/LIN- CELLS OF PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA AT DIAGNOSIS VS. 12 MONTHS OF FIRST-LINE NILOTINIB TREATMENT

EHA Library, Roberto Cairoli, 214834

NK-CELLS AND LOSS OF MOLECULAR RESPONSE AFTER TKI DISCONTINUATION IN CML PATIENTS

EHA Library, Yulia Davydova, 214835

POLYMORPHISMS IN MULTIDRUG RESISTANCE TRANSPORTER GENES AFFECT THE DURATION OF MOLECULAR RESPONSE TO NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS

EHA Library, Federica Loscocco, 214837

MYELOID CELL POPULATION DYNAMICS IN TKI-TREATED CML

EHA Library, Sieghart Sopper, 214838

THE EFFECT OF PREGNANE X RECEPTOR SNP AND TKI TROUGH CONCENTRATION ON CLINIC RESPONSE AND TOXICITY AMONG CHINESE CML PATIENTS.

EHA Library, Jiang Zhiping, 214839

WT1 EXPRESSION PREDICTS THE RESPONSIVENESS OF CHRONIC MYELOID LEUKEMIA TO FIRST LINE THERAPY OF TYROSINE KINASE INHIBITOR

EHA Library, Eleonora Toffoletti, 214840

LONG-TERM TREATMENT-FREE REMISSION (TFR) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FOLLOWING FRONTLINE (1L) NILOTINIB (NIL): RESULTS FROM ENESTFREEDOM

EHA Library, Giuseppe Saglio, 214841

BOSUTINIB VERSUS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN THE BFORE TRIAL: 24-MONTH FOLLOW-UP

EHA Library, Carlo Gambacorti-Passerini, 214842